Logo

    lipids

    Explore " lipids" with insightful episodes like "Not All Rumen-Protected Products Are Created Equal", "Ketosis and Body Science with Returning Guest Dave Champion, Ph.D.! 580", "2023 ASDA Winners & Organizers", "Reinventing Lipid Nanoparticles - Dr. John Lewis" and "Circulating Metabolites Associated with Albuminuria in a Hispanic/Latino Population" from podcasts like ""Real Science Exchange", "Boundless Body Radio", "Real Science Exchange", "Talking Biotech with Dr. Kevin Folta" and "Clinical Journal of the American Society of Nephrology (CJASN)"" and more!

    Episodes (40)

    Not All Rumen-Protected Products Are Created Equal

    Not All Rumen-Protected Products Are Created Equal

    This episode is from a webinar presented by Dr. Clay Zimmerman, Director of Technical Services at Balchem. To view the full webinar and access the slides referenced during this podcast, visit balchem.com/realscience and scroll down to the webinar presented on December 12th, 2023.

    Dr. Zimmerman begins with an overview of Balchem’s microencapsulation technologies in both human nutrition and health and animal nutrition and health businesses. (0:31)

    Encapsulation is a generic term, and huge differences can exist between products that protect the same compound. Balchem’s microencapsulation technology consists of packaging a substance in a lipid capsule for protection. Encapsulates can differ in design, technology, and performance. When it comes to performance in ruminant encapsulates, stability in feed mixing and TMRs and animal performance are evaluated. (6:50)

    Lipid encapsulation usually comes in one of two forms, a matrix encapsulation or a true encapsulation. A good analogy for matrix encapsulation is chocolate chip cookie dough, where some active compound is always at the surface. In the rumen, this leads to reduced protection and stability. True encapsulation, often called single-layer or multiple-layer encapsulation, is analogous to an m&m where there is no active compound at the surface, and this leads to greater protection and stability in the rumen.  (12:00)

    So why do we encapsulate nutrients for ruminants? In general, for targeted delivery within the gastrointestinal tract of the animal because rumen fermentation often results in massive breakdown of most of these important compounds. For example, choline chloride is almost completely degraded in the rumen. (18:30)

    When developing or improving rumen-protected products for nutrients such as choline chloride, methionine, lysine, or niacin, the primary goal is to protect them as much as possible from ruminal degradation while achieving post-ruminal absorption. Once prototypes have good ruminal stability and good intestinal release, the next step is feed and mixing stability. Dr. Zimmerman goes on to showcase different research techniques for evaluating encapsulates in these three areas as well as in animal performance. (20:39)

    In summary, there are many differences in encapsulated products for dairy cows, due to the design of products; types, amount, and composition of coatings; manufacturing differences; and differences in nutrient content, bioavailability, and feed stability. True encapsulates, or multi-layered coating products, are preferred for ruminant applications due to their higher levels of ruminant and feed stability. Four really important features of a good ruminant encapsulate are good ruminal stability, good nutrient bioavailability, feed and TMR stability, and ultimately biological performance. (47:05)

    Dr. Zimmerman then answers questions from the webinar audiences about in vitro techniques and bioavailability, coating ingredients, the importance of base diet for rumen fluid donors in in vitro techniques, variation in products from in vitro to in vivo results, how long it takes to develop a new encapsulated product (Balchem spends years and even decades researching before a product release), and why nutrient contents differ so much in similar encapsulated products on the market. (49:58)

     

    Please subscribe and share with your industry friends to bring more people to join us around the Real Science Exchange virtual pub table.  

    If you want one of our new Real Science Exchange t-shirts, screenshot your rating, review, or subscription, and email a picture to anh.marketing@balchem.com. Include your size and mailing address, and we’ll get a shirt in the mail to you.

    Ketosis and Body Science with Returning Guest Dave Champion, Ph.D.! 580

    Ketosis and Body Science with Returning Guest Dave Champion, Ph.D.! 580

    Dave Champion, Ph. D. is a returning guest on our show! Be sure to check out his first appearance on episode 121, and his second appearance on episode 358 of Boundless Body Radio!

    Dave Champion is a former Army Ranger with a law enforcement background. In the private sector, Dave is a businessman turned journalist, having hosted his own radio and television shows from 2000 through 2018. In addition to being a physiologist, with a doctoral degree in Political Philosophy, Champion has an extensive background in legal studies.

    Dave has written the groundbreaking and widely acclaimed Income Tax: Shattering The Myths.

    His second book Body Science: The New 21st Century Understanding Of How Your Physiology Really Works, Leave The Myths And Lies Behind, Get Healthier Than You (Or Your Doctor) Ever Imagined And Avoid Chronic Disease.is the result of his research into the core principles of human physiology, leading to a visionary understanding of how every person on the planet can get healthy, stay healthy, and reduce their odds of getting a diagnosis of a chronic disease to virtually zero.

    It is one of my favorite books on the subject, and will be the topic of our discussion today!

    Find Dave at-

    https://drreality.news/

    Book- Body Science

    TW- @DrReality5

    Rumble- @Dave Champion, Ph. D.

    FB- Busy Keto Life with Dr. Dave Champion

    Find Boundless Body at-

    myboundlessbody.com

    Book a session with us here!

    2023 ASDA Winners & Organizers

    2023 ASDA Winners & Organizers

    Today’s episode was filmed at the American Dairy Science Association Annual Meeting in Ottawa, Ontario, Canada. Joining us are the ADSA organizers and research winners to discuss their projects. Dr. Clay Zimmerman is our co-host this week. 

    Our first guests are Dr. Corwin Nelson, University of Florida and Kari Estes, Balchem. Dr. Nelson is the overall committee chair for the conference and said more than 1,300 abstracts were submitted. Of those, 1,254 were accepted to present at the ADSA conference. (1:44) Ms. Estes, who was a poster judge mentioned she looks for the aesthetics of the poster, but was also impressed with the rigor of research, especially with the winning posters. (5:22) 

    Our next guests are presentation winner, Ursula Abou-Rjeileh, Michigan State University and her advisor, Dr. Andres Contreras, Michigan State University. Ursula is a second-time winner and her research focuses on the effects of fatty acids on lipid accumulation and mitochondrial function in the post-partum phase. Her research showed that supplementing oleic acid with pulmonary acid, especially post-partum means cows don’t lose a lot of body weight. Her presentation name is Oleic acid promotes lipid accumulation and improves

    mitochondrial function in bovine adipocytes.(10:11) 

    Our third set of guests includes master’s poster winner Corienne Gammariello, The Ohio State University - Wooster and her advisor Dr. Ben Enger, The Ohio State University - Wooster. Corienne spoke about their research methods and how unique they were. She used dead bacteria and was able to elicit an immune response of an udder half, they used a split udder design model. Her poster title is Killed Staphylococcus aureus intramammary challenge

    induces subclinical mastitis and clear changes in milk composition but not milk yield.(15:11) 

    Next, we have Richard Lobo, winner of the Ph.D poster contest, from the University of Florida. Richard’s research was trying to replace soybean milk with algae. He saw that replacing 100% of soybean meal results in no fermentation. (20:15) More research is needed, because it is not yet known if protein that was not degraded in the rumen is going to be degraded later on, and absorbed. So we are still in the process of understanding how to use these protein sources with dairy cows. His poster title is Utilization of algae biomass as a partial replacement for

    soybean meal in the diet of dairy cows in vitro. (21:25) 

    Our last guests are Luke Quian, Cornell University and Connor McCabe, University of California Davis, who are the President and Vice President of the GSD (Graduate Student Division) at ADSA. Connor said that scientific presentation is a large reason to attend ADSA, but there are equal benefits and opportunities through networking, career development and professional pieces. (28:52) 

    Be sure to subscribe so you don’t miss the additional highlights from the 2023 ADSA Annual Meeting in future podcast episodes. 

    If you want one of our new Real Science Exchange t-shirts, screenshot your rating, review, or subscription, and email a picture to 

    anh.marketing@balchem.com. Include your size and mailing address, and we’ll get a shirt in the mail to you.

    Reinventing Lipid Nanoparticles - Dr. John Lewis

    Reinventing Lipid Nanoparticles - Dr. John Lewis

    Lipid nanoparticles have been around for decades, but they took a spotlight in the delivery of the COVID19 mRNA-based vaccines. This chemical cage can fuse with cell membranes and deliver a specific payload to a cell. While the delivery to specific cells is routine, are there ways to improve the system to have more specific therapeutic benefit. Dr. John Lewis of Entos discusses lipid nanoparticle chemistry and new formulations that exhibit enhanced capacity to target specific locations and deliver payloads more effectively. We also discuss the current therapies that may benefit from the new technologies. 

    Questions Answered on ART Safety and Tolerability in Aging Patients and Populations With Cardiometabolic Toxicities

    Questions Answered on ART Safety and Tolerability in Aging Patients and Populations With Cardiometabolic Toxicities

    In this episode, Marta Boffito, MD, PhD, FRCP, and Jens D. Lundgren, MD, DMSc, address key considerations when evaluating antiretroviral therapy safety and tolerability in aging patients and those with possible cardiometabolic toxicities, including:

    • Monitoring for cardiometabolic syndromes (eg, lipid panels, coronary artery calcification scores)
    • Approaching antiretroviral-related weight gain in clinical practice
    • Interpreting results from RESPOND on cardiovascular risk with integrase strand transfer inhibitors
    • Collaborating with other specialties (eg, cardiologists, dietitians) to provide a multidisciplinary approach for managing comorbidities, including prevention and management

    Faculty

    Marta Boffito, MD, PhD, FRCP
    Consultant Physician/Professor
    HIV/Research
    Chelsea and Westminster Hospital
    Imperial College London
    London, United Kingdom

    Jens D. Lundgren, MD, DMSc
    Professor
    Rigshospital, University of Copenhagen 
    Director
    Centre of Excellence for Health, Immunity and Infection (CHIP)
    Rigshospital, University of Copenhagen
    Copenhagen, Denmark

    Link to full program:
    http://bit.ly/3PM3nYe

    Link to downloadable slides: 
    http://bit.ly/3WgYycz

    Selecting First-line ART in Treatment-Naive Persons With HIV

    Selecting First-line ART in Treatment-Naive Persons With HIV

    In this episode, Princy N. Kumar, MD, FIDSA, MACP, discusses key considerations for selecting ART in treatment-naive persons with HIV. Her discussion includes:

    • DHHS Treatment Guideline recommendations
    • Choosing among first-line recommended integrase inhibitors
    • Recommended regimens for rapid ART start
    • Select key studies in treatment-naïve adults:
      • AMBER study of virologic response with DRV/COBI/FTC/TAF vs DRV/COBI + TFC/TDF
      • DRIVE-AHEAD and DRIVE-FORWARD efficacy study results, including resistance analyses of DOR + 2 NRTIs vs EFV or (DRV + RTV) + 2 NRTIs
      • Safety and efficacy results from GEMINI-1 and GEMINI comparing DTG + 3TC vs DTG + FTC/TDF
    • The current/possible role of boosted PIs and NNRTIs
    • Selection considerations between TDF and TAF

    Presenter:
    Princy N. Kumar, MD, FIDSA, MACP
    Professor of Medicine and Microbiology
    Chief, Division of Infectious Diseases and Travel Medicine
    Senior Associate Dean of Students
    Georgetown University School of Medicine
    Washington, DC

    Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.

    Link to full program:
    https://bit.ly/3VIsDTg

    Follow along with the slides:
    https://bit.ly/3PYy1zn

    Ketosis Is Our Natural State with Dave Champion PhD! 358

    Ketosis Is Our Natural State with Dave Champion PhD! 358

    Check out our new Patreon page! Get access to the Boundless Body Radio Premium Podcast, with a new episode added every other week! Other perks include early releases of our episodes, extended video content, and group and one on one coaching!

    Dave Champion, PhD is a returning guest on our show! Be sure to check out his first appearance on our podcast on episode 121 of Boundless Body Radio! Dave Champion is a former Army Ranger with a law enforcement background. In the private sector, Dave is a businessman turned journalist, having hosted his own radio and television shows from 2000 through 2018. In addition to being a physiologist, with a doctoral degree in Political Philosophy, Champion has an extensive background in legal studies. Dave has written the groundbreaking and widely acclaimed Income Tax: Shattering The Myths. His second book Body Science: The New 21st Century Understanding Of How Your Physiology Really Works, Leave The Myths And Lies Behind, Get Healthier Than You (Or Your Doctor) Ever Imagined And Avoid Chronic Disease.is the result of his research into the core principles of human physiology, leading to a visionary understanding of how every person on the planet can get healthy, stay healthy, and reduce their odds of chronic disease to virtually zero. It is one of my favorite books on the subject, and will be the topic of our discussion today!

    Find Dave at-

    https://drreality.news/

    Book- Body Science

    FB- Busy Keto Life with Dr. Dave Champion

    Dave's CAC Score Video on YouTube

    Find Boundless Body at-

    myboundlessbody.com

    Book a session with us here! 

    Find Boundless Body at-

    myboundlessbody.com

    Book a session with us here!

    Weight Gain and Cardiometabolic Toxicities in Patients With HIV

    Weight Gain and Cardiometabolic Toxicities in Patients With HIV

    In this episode, listen to Priscilla Y. Hsue, MD, and Jens D. Lundgren MD, DMSc, discuss the latest data about ARV-related weight gain and cardiometabolic toxicities in PWH. Hear faculty:

    • Review risk factors associated with significant weight gain
    • Consider possible implications of weight gain and cardiometabolic toxicities
    • Share their approaches to ARV-related weight gain and/or cardiometabolic toxicities

    Faculty:

    Priscilla Y. Hsue, MD
    Professor of Medicine
    University of California at San Francisco
    San Francisco General Hospital
    San Francisco, California

    Jens D. Lundgren, MD, DMSc
    Professor
    Rigshospital, University of Copenhagen
    Director
    Centre of Excellence for Health, Immunity and Infection (CHIP)
    Rigshospital, University of Copenhagen
    Copenhagen, Denmark

    Link to full program:
    https://bit.ly/3PM3nYe

    🎙Risk Factors You Need to Know for Your Heart Health Ep 30

    🎙Risk Factors You Need to Know for Your Heart Health Ep 30

    This month's MedEvidence! podcast is a three-part series on "What to do after a Heart Attack or Stroke?" In the first MedEvidence segment we established that people who have had either a heart attack or stroke have a high risk for a repeat procedure or event. We also discussed knowing who's on your Heart Health Team, PCP, specialist, and family. What's abnormal, normal, and what to do when symptoms last greater than 20 minutes? In this 15-minute episode, Doctors, Michael Koren and Albert Lopez DO discuss the Risk Factors You Need to know for your heart health. 


    You will learn:

    • What modifiable risk factors are 
    • What non-modifiable risk factors are
    •  What you can do to help your risk factors
    • How clinical trials and research find other drug benefits
    • How to be involved in a clinical trial


    Dr. Michael Koren is a practicing cardiologist and CEO at ENCORE Research Group. He has been the principal investigator of 2000+ clinical trials while being published in the most prestigious medical journals. Dr. Koren received his medical degree cum laude at Harvard Medical School and completed his residency in internal medicine with a fellowship in cardiology at New York Hospital / Memorial Sloan-Kettering Cancer Center/ Cornell Medical Center.

    Dr. Albert Lopez, DO practices Internal Medicine with Millennium Physician Group in Jacksonville, Florida. He is also a Principal Investigator with ENCORE Research Group specializing in lipid clinical trials. Dr. Lopez, DO completed his residency at the University of Pennsylvania and his Doctor of Osteopathic Medicine at Nova Southeastern University in Miami, Florida. He is known as one of the earliest evidence-based physicians in Jacksonville utilizing nutrition and lifestyle for disease prevention.
    I believe in "N" of one" because "N of one" is about the patient. If it is not about the patient, then it is about nothing. - Dr. Albert Lopez, DO

    Original Air Date: June 17, 2022

    Be a part of advancing science by participating in clinical research

    Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.

    Follow us on Social Media:
    Facebook
    Instagram
    Twitter
    LinkedIn

    Want to learn more checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com

    Powered by ENCORE Research Group
    Music: Storyblocks - Corporate Inspired

    Thank you for listening!

    Have you checked your insulin, glucose and cholesterol levels lately?

    Have you checked your insulin, glucose and cholesterol levels lately?

    Do you worry about your clothing size or whether your butt looks too big or not big enough? (hello everchanging and unrealistic beauty standards). Let’s take a look at some of the numbers that REALLY matter.

    On this episode, Dr Sarah explains what your insulin, glucose and cholesterol levels should be.

    Come for the juicy science, stay for the nickname Sarah once gave her liver in Med School.

    The information in this podcast is for general use, always consult your doctor or physiotherapist before undertaking a new exercise program.

    Contact us: womenlikeyoupodcast@gmail.com

    WLY resources and recommendations:

    AusDRisk calculator https://www.health.gov.au/resources/apps-and-tools/the-australian-type-2-diabetes-risk-assessment-tool-ausdrisk

    Aerobic exercise and lipids and lipoproteins in women: a meta-analysis of randomized controlled trials https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447858/pdf/nihms34518.pdf

    WLY newsletter subscription 

    The Women Like You podcast is recorded on the lands of the Gadigal people of the Eora nation. We pay our respects to elders past, present and emerging. We acknowledge Aboriginal and Torres Strait Islander peoples as the First Australians and Traditional Custodians of the land where we live, work, and exercise.

    See omnystudio.com/listener for privacy information.

    Key Decisions in HIV Care: Polypharmacy and Cardiovascular Risk Considerations in Older PWH

    Key Decisions in HIV Care: Polypharmacy and Cardiovascular Risk Considerations in Older PWH

    In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for ART use in older PWH, including:

    • DHHS, EACS, IAS, and WHO recommendations for first-line ART
    • Virologic outcomes for older PWH in clinical trials and results from the HealthHIV Second Annual National Survey
    • Polypharmacy and its potential consequences, including common non-ARV medications prescribed in the VACS cohort, drug–drug interactions with common concomitant medications, common comorbidities in older PWH, and drug–disease state interactions including renal and hepatic impairment
    • Cardiovascular risk considerations including data from the D:A:D study and RESPOND cohort and lipid changes in the TANGO study of switching to DTG/3TC from TAF-based ART

    Presenters:

    Jonathan Appelbaum, MD, FACP, AAHIVS
    Laurie L. Dozier Jr, MD, Education Director
    Professor of Internal Medicine  
    Chair, Department of Clinical Sciences
    Florida State University College of Medicine
    Tallahassee, Florida  

    Jens D. Lundgren, MD, DMSc
    Professor
    Rigshospital, University of Copenhagen
    Copenhagen, Denmark
    Director
    Centre of Excellence for Health, Immunity and Infection (CHIP)
    Rigshospital, University of Copenhagen
    Copenhagen, Denmark  

    Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

    Follow along with the slides at:
    https://bit.ly/3miT6qH

    See the entire program at: 
    https://bit.ly/2TXTYWx

     

    Key HIV Studies Influencing My Practice Following IDWeek 2021 – Audio Recap

    Key HIV Studies Influencing My Practice Following IDWeek 2021 – Audio Recap

    In this episode, Darcy Wooten, MD, discusses new HIV data from IDWeek 2021, including:

    • A rapid test-and-treat program to start DTG/3TC in patients newly diagnosed with HIV (STAT)
    • Efficacy when switching from 3-drug to 4-drug TAF-based regimens to DTG/3TC (TANGO)
    • Virologic outcomes with 2-drug vs 3-drug ART regimens (Trio Health HIV Network Study)
    • Metabolic complications in treatment-naive patients (Study 1489 and Study 1490)
    • Resistance analysis of an investigational agent, lenacapavir (CALIBRATE)
    • The Positive Perspectives Survey to evaluate the U=U Educational Campaign in North American patients

    Presenter:

    Darcy Wooten, MD
    Associate Professor of Medicine
    Division of Infectious Diseases and Global Public Health
    Department of Medicine
    University of California, San Diego
    San Diego, California

    Link to full program:
    https://bit.ly/3BCHF2E

    S2-E42.2 - How FGFs Work In The Body And What This Means For NAFLD And NASH

    S2-E42.2 - How FGFs Work In The Body And What This Means For NAFLD And NASH

    Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation focuses on the roles fibroblast growth factors (FGFs) play in fat metabolism, appetite and other issues related to Fatty Liver disease.


     After a simple opening from Roger Green, this conversation includes 4 key elements:

    1:06 - Arun Sanyal discusses the different ways that fibroblast growth factors work in the body
    4:21 - Stephen Harrison share some background on how fat gets into the liver in the first place
    6:16 - Arun Sanyal describes the specific differences between FGF 2, 3 and 4 receptors in terms of physiologic impact and the role of adiponectin
    9:50 - Stephen Harrison and Arun Sanyal comment briefly on the impact of adiponectin in terms of liver scarring

    S2-E42.1 - FGF drugs in Development - A Promising Class of Agents

    S2-E42.1 - FGF drugs in Development - A Promising Class of Agents

    Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGF) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation focuses on FGF drug development to date.

    After a simple opening from Roger Green, this conversation includes 4 key elements:

    1:05 - Roger Green discusses recent history of FGF agents and podcast episodes discussing them
    2:11 - Stephen Harrison discusses the efruxifermin BALANCED Phase 2a trial in F2/F3 NASH and Cohort C with cirrhosis patients
    6:59 - Arun Sanyal and Stephen Harrison discuss future prospects for FGF-21 agents
    10:34 - Arun Sanyal discusses specific receptor targets for different FGF agents and why they matter

    This episode has specific discussions of efruxifermin and mentions of pegbelfermin and MK-3655, the former NGM-313.

    A Cholesterol Clinic- Body Science with Dave Champion, Ph.D.! 121

    A Cholesterol Clinic- Body Science with Dave Champion, Ph.D.! 121

    Dave Champion, Ph. D. caught my attention when he reached out to see if I'd like to read his book, Body Science. I did, and I found it to be a treasure. Dave does an incredible job describing the cholesterol and fat delivery systems in the body. If you or anyone you love needs answers to their questions about cholesterol, dietary fat, longevity, and chronic diseases, this is a must-listen! Please check out his book, Body Science, and continue researching this topic if you want more information! It couldn't be more important, and we are so grateful for Dave and his work!

    Find Dave at-

    https://drreality.news/

    Book- Body Science

    Dave's CAC Score Video on YouTube

    Find Boundless Body at-

    myboundlessbody.com

    Book a session with us here!

    NEJM Interview: Dr. Gary Gibbons on progress in understanding, preventing, and treating atherosclerotic cardiovascular disease.

    NEJM Interview: Dr. Gary Gibbons on progress in understanding, preventing, and treating atherosclerotic cardiovascular disease.
    Dr. Gary Gibbons is the director of the National Heart, Lung, and Blood Institute. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. G.H. Gibbons, C.E. Seidman, and E.J. Topol. Conquering Atherosclerotic Cardiovascular Disease — 50 Years of Progress. N Engl J Med 2021;384:785-788.

    Geeky Magic - Become A Fat Burner In 28 Days

    Geeky Magic - Become A Fat Burner In 28 Days

    This week on Geeky Magic we take a look at Chapter 8 “Become A Fat Burner In 28 Days” from my new book The Betty Body. Over the last few weeks, we have taken a dive into each chapter to discuss the struggles, successes, and stories behind the book. This chapter is all about how to structure a ketogenic diet for women. We dive into the emerging science around cholesterol and how the conversation around cholesterol has been misleading.  Join The Better! Community On Facebook. Get the show notes here.

    Ep#20 Dave Feldman - Destroying Cholesterol Myths Pt.2 - Citizen Scientist Series

    Ep#20 Dave Feldman - Destroying Cholesterol Myths Pt.2 - Citizen Scientist Series

    Dave Feldman is a senior software engineer and entrepreneur who uses his engineering mindset to look at biological systems as a whole.  Dave explores how biological networks function and often finds data that contradicts our current way of thinking in regards to health and cholesterol.

    Dave began a Low Carb High Fat diet in April 2015 and started researching everything he could about carbohydrate restriction and lipid function - with special emphasis on cholesterol - when his lipid numbers spiked substantially after going on the diet. As an engineer he spotted a pattern in the lipid system that’s very similar to distributed objects in networks.

    Dave has since learned a ton on the subject - both through research and experimentation - which has revealed some very powerful data. With this new general theory Dave shifted around his cholesterol substantially without any drugs or special supplements of any kind.  Dave went on to create The Cholesterol Code website where he shares his research and helps others understand lipids in order to achieve better health goals.

    ⭐️To contact or follow Dave Feldman:

    Website: 👉 https://cholesterolcode.com

    Facebook: 👉 https://www.facebook.com/groups/CholesterolCode

    Twitter: 👉 @daveketo

    Instagram: 👉 @davedeldmanketo

    ⭐️ Products mentioned on the show:

    KETO CHOW: 👉 http://shop.ketochow.xyz/?aff=81&ref=carriebrown  (10% discount)

    Redmond Real Salt: 👉 https://shop.redmond.life?afmc=carriebrown  Code: carriebrown (15% discount)

    Be sure to rate, subscribe and leave a comment!

    To support the show and gain access to private groups, rewards, swag, and become a Kitchen or Fatty Joe Show Rockstar, use these links:

    http://www.patreon.com/thefattyjoeshow

    or http://www.patreon.com/carriebrown

    Check out our website at http://www.thefattyjoeshow.com

    If you want to sport some Fatty Joe Show swag like t-shirts coffee mugs and other cool items, go to:

    https://www.zazzle.com/collections/the_fatty_joe_show-119044829655147361?rf=238386382098264295

    For recipes, articles, product discounts, Cookbooks, and Cooking Masterclasses go to: http://www.carriebrown.com

    Carrie Brown Masterclasses:👉 https://carriebrown.com/keto-cooking-masterclasses

    Cookbooks by Carrie Brown:👉 https://carriebrown.com/cookbooks-carrie-brown-keto-lchf-lowcarb

    For our YouTube Channel with cooking videos, Vidcast episodes, Keto 101, product reviews, and more go to: https://www.youtube.com/c/TheRealCarrieBrown

    Facebook pages: Carrie Brown and The Fatty Joe Show

    Members Group: The Keto Kitchen with Carrie Brown and The Fatty Joe Show with Yogi Parker

    Instagram: @thefattyjoeshow, @therealcarriebrown, @therealyogiparker

    Twitter: @realcarriebrown, @realyogiparker

    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io